Robert Marcus
Stock Analyst at JP Morgan
(1.47)
# 3,584
Out of 5,106 analysts
23
Total ratings
55.56%
Success rate
-1.18%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Robert Marcus
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PEN Penumbra | Upgrades: Overweight | $275 → $370 | $315.95 | +17.11% | 5 | Dec 18, 2025 | |
| IART Integra LifeSciences Holdings | Upgrades: Neutral | $75 | $12.59 | +495.71% | 2 | Dec 17, 2021 | |
| BDX Becton, Dickinson and Company | Downgrades: Neutral | $265 | $195.67 | +35.43% | 10 | Aug 6, 2021 | |
| GKOS Glaukos | Downgrades: Underweight | $50 | $116.18 | -56.96% | 2 | Oct 8, 2020 | |
| TMDX TransMedics Group | Downgrades: Neutral | $15 | $128.20 | -88.30% | 2 | Oct 8, 2020 | |
| ATRC AtriCure | Maintains: Overweight | $48 → $57 | $40.54 | +40.60% | 2 | Jul 29, 2020 |
Penumbra
Dec 18, 2025
Upgrades: Overweight
Price Target: $275 → $370
Current: $315.95
Upside: +17.11%
Integra LifeSciences Holdings
Dec 17, 2021
Upgrades: Neutral
Price Target: $75
Current: $12.59
Upside: +495.71%
Becton, Dickinson and Company
Aug 6, 2021
Downgrades: Neutral
Price Target: $265
Current: $195.67
Upside: +35.43%
Glaukos
Oct 8, 2020
Downgrades: Underweight
Price Target: $50
Current: $116.18
Upside: -56.96%
TransMedics Group
Oct 8, 2020
Downgrades: Neutral
Price Target: $15
Current: $128.20
Upside: -88.30%
AtriCure
Jul 29, 2020
Maintains: Overweight
Price Target: $48 → $57
Current: $40.54
Upside: +40.60%